CLAIM #2411 · AbbVie Inc (ABBV) · 2024Q2 earnings call · Jul 25, 2024 · due Dec 31, 2025
“And we do expect another step down in absolute dollar terms in 2025 for that erosion as well.”
Scott Reents · CFO
CANNOT_DETERMINE
resolved by a revision, graded at the moved level · official band 5 percent
Committed
we do expect another step down in absolute dollar terms in 2025 for that erosion
Reported
US Humira revenues of $3.5 billion a decrease of $500 million reflecting higher erosion from biosimilar competition
Verify independently
SEC filings for ABBV ↗ · Claim quote is verbatim from the 2024Q2 earnings call.